onl1204
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2019 (NCT03780972)
Timeline
Indications
Mechanism of action
FASLG inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSXNA75YDV3F ↗
- ChEMBLCHEMBL4298066 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06659445 | Phase 2 | Mar 31, 2025 | ONL Therapeutics |
| NCT05730218 | Phase 2 | Apr 4, 2023 | ONL Therapeutics |
| NCT05160805 | Phase 1 | Feb 28, 2022 | ONL Therapeutics |
| NCT04744662 | Phase 1 | Jul 8, 2021 | Center for Eye Research Australia, ONL Therapeutics |
| NCT03780972 | Phase 1 | Feb 1, 2019 | ONL Therapeutics, Sydney Eye Hospital |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ONL Therapeutics | For profit | 5 | 5 | 2 | 2019 |
| Center for Eye Research Australia | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Sydney Eye Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1